Proprietary GENEART Production Process

The freedom to operate status of GENEART’s optimization and production process (based on regular patent searches) and the fact that all essential steps of GENEART’s gene optimization and production process are GENEART’s own proprietary developments or are in-licensed from third parties offers our customers maximum protection for their future products against a potential infringement of third parties’ rights in the optimization and production process used by GENEART.

Gene Optimization:

WO2004059556A3: Method and devices for optimizing a nucleotide sequence for the purpose of expression of a protein

WO2006015789A3: Method for modulating gene expression by modifying the CpG content

Gene Synthesis, Variant and Library Construction:

US Patent 6,472,184: Method for producing nucleic acid polymers
License from F. Hoffmann-La Roche Ltd. to practice the polymerase chain reaction process (PCR) to manufacture in Germany and to sell worldwide DNA molecules (European Patent Nos. 0 200 362 and 0 201 184, United States Patent Nos. 4.683.195 and 4.683.202)
License from City of Hope to use the primer extension process to manufacture and sell DNA molecules under US Patent No. 5,750,380
DE 10 2005 037 351.8 Methods for autonomous gene evolution of a protein in vitro
DE 1 DE 10 2005 037 349.6 Methods for autonomous gene evolution of a protein in vivo

Subcloning & other Technologies:

License of Invitrogen IP Holdings Inc. to use the Gateway® technology under U.S. Patent Nos. 5,888,732,6,143,557,6,171,861, 6,270,969, 6,277,608, and 6,720,140, and / or other pending U.S. and foreign patent applications owned by Invitrogen Corporation
License of Dyax Inc. to practice the bacteriophage display inventions (US Patent Nos. 5,223,409, 5,403,484, 5,571,698, 5,837,500 and / or other pending U.S. and foreign patent applications) for sale of a SH3 phage display library and for funded customer research

PDF